Haemonetics Expects to Post Q2 Revenue Results Below Street View

Haemonetics (HAE), a healthcare company, said that, based on preliminary information, it expects to report revenue of $220 million and adjusted earnings approximating $0.40 per diluted share for its second fiscal 2016 quarter ended September 26, 2015.

Ten analysts, on average, were predicting revenue of $226.5 million and earnings of $0.39 per diluted share.

The company has also revised its previously-issued revenue and adjusted earnings guidance for the full fiscal year 2016.

Revenue is now expected to be within the range of $910-$920 million, representing 0-1% growth, which is below previous guidance of 4-6% growth. Analysts were looking for $946.8 million, or 4% growth.

Fiscal year 2016 adjusted earnings guidance is revised to a range of $1.65 – $1.75 per share, which is below the previous guidance range of $1.98 – $2.08 per share. Analysts on average had predicted earnings of $2.02 per diluted share.

Shares of the Braintree, Massachusetts-based company closed down 2.2% at $33.38 on Monday, stretching this year’s slump to 11%

Previous articleVeritiv Files $200 Mln Mixed Shelf Offering
Next articleSilicon Motion Technology Sees Q3 Sales At Upper End of Prior Guidance
John Smith
An engineer by degree and blogger by choice. Interested in writing the latest updates happening around the world. Loves to binge watch tv-series and movies.


Please enter your comment!
Please enter your name here